Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Medication Safety

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, community medical centers have historically provided accessible, patient-centered care, emphasizing preventive health and the management of common ailments. This heritage of disseminating reliable health knowledge has empowered individuals to make informed decisions about their well-being, often focusing on lifestyle factors and routine medical interventions. Transitioning from this general health framework, a more specialized area of concern emerges when considering the long-term use of certain prescription medications. Among these, bisphosphonates such as Fosamax have been widely prescribed for bone-related conditions. As the scope of health information narrows from broad preventive advice to specific pharmacovigilance, attention shifts to potential adverse effects associated with sustained drug exposure.

Understanding Fosamax and Its Uses

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ).

What Is Osteonecrosis of the Jaw?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but frequently associated with dental procedures such as tooth extraction, dental implants, or boney surgery, as well as local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ can include pain, swelling, infection, and exposed bone that fails to heal over several weeks. Diagnosis typically involves clinical examination and imaging, with a focus on ruling out other causes such as malignancy or metastatic disease. The condition is particularly concerning because it can lead to significant morbidity, including chronic pain, difficulty eating, and secondary infections.

Mechanisms Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate suppress bone turnover by inhibiting osteoclast-mediated bone resorption. In the jawbone, which has a high rate of remodeling due to constant mechanical stress from chewing and the presence of teeth, this suppression can lead to microdamage accumulation and impaired healing. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and may alter immune responses, increasing susceptibility to infection. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the unique vulnerability of the jawbone to bisphosphonate therapy.

Risk Factors and Clinical Evidence

Known risk factors for ONJ include invasive dental procedures, diagnosis of cancer, concomitant therapies such as chemotherapy, corticosteroids, and angiogenesis inhibitors, poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in clinical trials was low and not statistically different from placebo, though post-marketing reports have confirmed the association.

Causation Considerations for Affected Patients

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates causation assessment, as ONJ can also occur spontaneously or due to other risk factors. For patients who develop ONJ after starting Fosamax, particularly those with no other identifiable risk factors, a causal link may be plausible. However, the presence of concomitant risk factors such as dental procedures or cancer treatments can confound the association. The label advises discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), indicating that the drug is considered a contributing factor. In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, as documented in prescribing information and supported by mechanistic research. The risk is influenced by duration of use, dental procedures, and other patient-specific factors. Adequate warnings are provided in the label, but patients and healthcare providers should remain vigilant, especially when invasive dental work is planned. For affected patients, causation may be established based on temporal association and exclusion of other causes, though individual cases require careful evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and what is it used for?

Does Fosamax cause osteonecrosis of the jaw?

Yes, Fosamax is associated with an increased risk of osteonecrosis of the jaw (ONJ), as documented in prescribing information and supported by mechanistic research. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while on Fosamax?

Known risk factors include invasive dental procedures, diagnosis of cancer, concomitant therapies such as chemotherapy, corticosteroids, and angiogenesis inhibitors, poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure.

How is causation between Fosamax and ONJ determined?

Causation involves establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients with no other identifiable risk factors, a causal link may be plausible, but individual cases require careful evaluation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.